TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03173053
Drug: Fusidic Acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet or ointment
Study: NCT03173053
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03173053
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouthwash or bodywash
Study: NCT03173053
Drug: Mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal ointment
Study: NCT03173053
Drug: Betadine
Normalized name: Betadine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shampoo
Study: NCT03801538
Drug: Peginterferon Alfa
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
Study: NCT03255512
Drug: Vericiguat (BAY1021189)
Normalized name: Vericiguat
DrugBank: Vericiguat (DB15456)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet
Study: NCT03255512
Drug: Isosorbide mononitrate (ISMN)
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/tablet or 60 mg/tablet
Study: NCT00398931
Drug: MK0217, alendronate sodium / Duration of Treatment : 5 Years
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01125020
Drug: gemcitabine and oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
Study: NCT00505583
Drug: MOA-728
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03357055
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
Study: NCT01760161
Drug: Isotonic potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
Study: NCT03735433
Drug: 162mg aspirin dose
Normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 pills of 81mg aspirin
Study: NCT02684266
Drug: SHR6390
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
Study: NCT02332980
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02332980
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00534794
Drug: Elestat
Normalized name: Elestat
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Elestat BID for 2 days
Study: NCT00534794
Drug: Pataday
Normalized name: Pataday
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pataday QD for 2 days
Study: NCT03545191
Drug: Daridorexant 25 mg
Normalized name: daridorexant 25 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.
Study: NCT03545191
Drug: Daridorexant 50 mg
Normalized name: daridorexant 50 MG
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.
Study: NCT04560465
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous perioperative tranexamic acid was added into infusion of normal saline for the cases while placebo of intravenous water for injection was added into normal saline perioperatively for control
Study: NCT01769274
Drug: PF-05089771
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
Study: NCT01401257
Drug: PXT3003 Low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liquid,5 ml, twice a day, 12-month treatment
Study: NCT01401257
Drug: PXT3003 High Dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid,5 ml, twice a day, 12-month treatment
Study: NCT02311920
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00112346
Drug: Cetuximab + platinum + gemcitabine
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
Study: NCT00112346
Drug: Platinum + Gemcitabine
Normalized name: platinum
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 \& Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
Study: NCT02168725
Drug: briciclib
Normalized name: Briciclib
DrugBank: Briciclib (DB12004)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00492765
Drug: Interferon-beta-1a
Normalized name: Interferon-beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage and frequency as per label
Study: NCT02359201
Drug: V0018
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oromucosal - Single dose
Study: NCT03179163
Drug: Captopril Pill
Normalized name: captopril Pill
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACEi+SH
Study: NCT03179163
Drug: Enalapril Pill
Normalized name: enalapril Pill
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACEi
Study: NCT03179163
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diuretic
Study: NCT00598624
Drug: Treosulfan IV
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
Study: NCT04154150
Drug: Intravenous ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)
Study: NCT02326025
Drug: Olaratumab
Normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered IV
Study: NCT00644384
Drug: acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00287859
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
Study: NCT03653052
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
Study: NCT01427842
Drug: DEVINE vancomycin regimen
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
Study: NCT03236740
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
Study: NCT02151760
Drug: 18F-DCFPyL
Normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00310791
Drug: Hormone replacement therapy (estrogen/progestin)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
Study: NCT00310791
Drug: Dehydroepiandrosterone (DHEA)
Normalized name: DEHYDROEPIANDROSTERONE (DHEA) CAP/TAB
DrugBank: Prasterone (DB01708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg tablet, 1 daily
Study: NCT00321737
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
Study: NCT00321737
Drug: Dexlansoprazole MR
Normalized name: Dexlansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
Study: NCT00280878
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00280878
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00280878
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00280878
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02025751
Drug: Metoclopramide Nasal Spray
Normalized name: metoclopramide Nasal Spray
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
Study: NCT03237533
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be applied locally on the lesion
Study: NCT03097588
Drug: Netupitant
Normalized name: Netupitant
DrugBank: Netupitant (DB09048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg, Given PO, QD
Study: NCT03097588
Drug: Palonosetron Hydrochloride
Normalized name: Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg, Given PO, QD
Study: NCT01709734
Drug: galeterone
Normalized name: Galeterone
DrugBank: Galeterone (DB12415)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546843
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
Study: NCT02546843
Drug: Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisatracurium 0.15mg/kg intravenously
Study: NCT02546843
Drug: Nonspecific Neuromuscular Blockade reversal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
Study: NCT02546843
Drug: Specific Neuromuscular Blockade reversal
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
Study: NCT02546843
Drug: maintaining the depth of neuromuscular blockade - rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
Study: NCT02546843
Drug: maintaining the depth of neuromuscular blockade - cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
Study: NCT02940379
Drug: sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02940379
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: HCl syrup~Route of administration: oral
Study: NCT02940379
Drug: metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00181220
Drug: valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02794857
Drug: NP001
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02624726
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
Study: NCT02624726
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
Study: NCT03828448
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - anti-CD 20 monoclonal antibody administered via IV infusion
Study: NCT03828448
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - PI3K Delta Inhibitor oral daily dose
Study: NCT03431974
Drug: LD-Aminopterin oral capsule
Normalized name: aminopterin
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-folate treatment
Study: NCT01631513
Drug: Nucynta ER
Normalized name: Nucynta ER
DrugBank: Tapentadol (DB06204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 to 250 mg every 12 hours
Study: NCT02499315
Drug: AMG 357
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Study: NCT02530931
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
Study: NCT00399971
Drug: Ex vivo immunotherapy
Normalized name: Ex-vivo expanded placental adherent stromal cells
DrugBank: PLX-R18 (DB17989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusions, once a week, at least 6 to 12 months
Study: NCT03421041
Drug: Dexamethasone Oral Tablet
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone Oral Tablet，0.75mg/tablet
Study: NCT03944681
Drug: Droperidol Injectable Solution
Normalized name: droperidol Injection
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
Study: NCT00502801
Drug: doripenem
Normalized name: Doripenem
DrugBank: Doripenem (DB06211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
Study: NCT00003972
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003972
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003972
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003972
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003972
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003972
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00588640
Drug: d-Methadone
Normalized name: D-methadone
DrugBank: Dextromethadone (DB15198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 subjects to receive 40 mg d-Methadone twice a day
Study: NCT00588640
Drug: D-methadone
Normalized name: D-methadone
DrugBank: Dextromethadone (DB15198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Study: NCT01859741
Drug: OMP-59R5
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMP-59R5 administered intravenously
Study: NCT00911807
Drug: Cerebrolysin + donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Study: NCT00911807
Drug: Cerebrolysin + placebo
DrugBank: Cerebrolysin (DB16599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks).
Study: NCT00911807
Drug: Donepezil + placebo
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg.
Study: NCT03322384
Drug: epacadostat
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat will be administered orally, in pill form, twice daily until disease progression.
Study: NCT03322384
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
Study: NCT01859741
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered intravenously
Study: NCT01859741
Drug: Cisplatin or Carboplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT01524302
Drug: Ceftaroline
Normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg Q12h
Study: NCT01524302
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg QD
Study: NCT01955213
Drug: methylnaltrexone
Normalized name: Methylnaltrexone
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, \>114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
Study: NCT02497118
Drug: Endostatin
Normalized name: Endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostatin,7.5mg/m\^2,intravenous, d1-14;
Study: NCT02497118
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vinorelbine,25mg/m\^2,intravenous, d1, d8;
Study: NCT02497118
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin，75mg/m\^2 intravenous,divide into d1-3
Study: NCT02551575
Drug: Treatment of TCM
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks.
Study: NCT01618591
Drug: Single dose rifaximin 1650 mg
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study: NCT01583218
Drug: Betrixaban
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days
Study: NCT01583218
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days
Study: NCT03660436
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT03660436
Drug: MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days